Calimmune calimmune.com


Public lists: Pharma Startups (4732)

Calimmune is a clinical-stage biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune systems. Calimmune's lead product candidate for HIV, now in Phase I/II studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. Calimmune is developing a full product pipeline of therapeutic candidates to address the unique needs of individuals at different stages of HIV infecti...Show all

Calimmune is a clinical-stage biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune systems. Calimmune's lead product candidate for HIV, now in ...Show all

Company (Acquired)

Phone: 310-806-6240

Fax:

5151 East Broadway Boulevard
Suite 1020
Tucson, 85711
Arizona, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Calimmune $21.3M Aug 28, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Calimmune Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Desert AngelsAngel Investor (Group)Tucson, Arizona, United StatesSeries A - III, Series A - II, Series A, Angel - II, Convertible Note - II, Convertible Note, Angel
RA Capital ManagementAdvisoryBoston, Massachusetts, United StatesSeries B
Qualifying Therapeutic Discovery ProjectGovernmentWashington, DC, United StatesGrant
Alexandria Venture InvestmentsCorporate VenturePasadena, California, United StatesSeries B
See all 6 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Patents

Title Application Date Patent Date Status
(Patent / Application)
In vivo chemoselection with low dose thioguanine Nov 16, 2017 Application
Gene therapeutic for the treatment of hiv and uses thereof Nov 13, 2017 Application
Methods for discriminating between hiv-1 and lentiviral vectors Nov 13, 2017 Application
Bio-production of lentiviral vectors Nov 02, 2017 Application
Dual vector for inhibition of human immunodeficiency virus May 09, 2016 Application